1 2	f	Design and Analysis of Outcomes following SARS-CoV-2 Infection in Veterans			
3					
4 5	Valerie A. Smith, DrPH ^{1,2,3} , Theodore S. Z. Berkowitz, MS ¹ , Paul Hebert, PhD ^{4,5} , Edwin S. Wong, PhD ^{4,5} , Meike Niederhausen, PhD ^{6,7,8} , John A. Pura, PhD ¹ , Kristin Berry, PhD ^{4,12} , Pamela Green, MPH PhD ⁴ , Anna Korpak, PhD ¹² , Alexandra Fox, MS ¹² , Aaron Baraff, MS ¹² , Alex Hickok, MS ⁶ ,				
6	Anna Korna	12 Alexandra Fox MS ¹² Aaron Baraff MS ¹² Alex Hickok MS ⁶			
7	Trov A Shah	oumian, MPH PhD^{19} , Amy S.B. Bohnert, $PhD^{9,10}$, Denise Hynes, $PhD^{6,11}$,			
8	Edward I Boyk	o, MD MPH ¹² , George N. Ioannou, $MD^{4,13}$, Theodore J. Iwashyna, $MD^{9,14,15}$,			
9	C Barrett Bow	1 ling, MD ^{1,16,17} , Ann M. O'Hare, MD ^{4,18} , Matthew L. Maciejewski, Ph.D. ^{1,2,3}			
10	e. Buildt Bow				
11	¹ Center of Innovation to	Accelerate Discovery and Practice Transformation, Durham VA Medical Center, Durham,			
12	NC				
13		n Health Sciences, Duke University, Durham, NC			
14		nal Medicine, Department of Medicine, Duke University, Durham, NC			
15		h & Development Center of Innovation for Veteran-Centered and Value-Driven Care, and			
16		section, Veterans Affairs Puget Sound Health Care System, Seattle, WA			
17 18		stems and Population Health, University of Washington, Seattle, WA an Involvement in Care, VA Portland Health Care System, Portland, OR			
18 19		e University (OHSU), Portland, OR			
20		V School of Public Health, Portland, OR			
21		Janagement Research, Ann Arbor VA, Ann Arbor, MI			
22		siology and Psychiatry, University of Michigan Medical School, Ann Arbor, MI			
23		n and Human Sciences and Center for Quantitative Life Sciences, Oregon State University,			
24	Corvallis, OR				
25	¹² Seattle Epidemiologic Research and Information Center, VA Puget Sound, Seattle, WA				
26 27	 ¹³ Division of Gastroenterology, University of Washington, Seattle, WA ¹⁴ National Clinical Scholars Program, University of Michigan Medical School, Ann Arbor, MI 				
27 28	¹⁵ Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI				
20 29	¹⁶ Geriatric Research Education and Clinical Center, Durham VA Medical Center, Durham, NC				
30	¹⁷ Department of Medicine	e, Duke University, Durham, NC			
31	¹⁸ Division of Nephrology	, University of Washington, Seattle, WA			
32	¹⁹ Population Health: Health Solutions, Veterans Health Administration, Washington, DC				
33					
34					
35	Corresponding Author:				
36	Matthew L. Maciejewsl				
37	Department of Populati				
38	Duke University Medical Center				
39	Durham, NC 27705				
40	Phone: (919) 286-0411 ext. 5198				
41	e-mail: <u>mlm34@duke.edu</u>				
42	• ·				
43	ABSTRACT:	327 WORDS			
44	WORD COUNT:	2,896 WORDS			
45	TABLES:				
46	FIGURES:				
47 48	APPENDICES:	1			
48					
49 50		MAY 31, 2022			
50	V WIAT 31, 2022				

51

ABSTRACT

52

Background: Understanding how SARS-CoV-2 infection impacts long-term patient outcomes requires identification of comparable persons with and without infection. We report the design and implementation of a matching strategy employed by the Department of Veterans Affairs' (VA) COVID-19 Observational Research Collaboratory (CORC) to develop comparable cohorts of SARS-CoV-2 infected and uninfected persons for the purpose of inferring potential causative long-term adverse effects of SARS-CoV-2 infection in the Veteran population.

59 **Methods:** In a retrospective cohort study, we identified VA health care system patients who 60 were and were not infected with SARS-CoV-2 on a rolling monthly basis. We generated 61 matched cohorts utilizing a combination of exact and time-varying propensity score matching 62 based on electronic health record (EHR)-derived covariates that can be confounders or risk 63 factors across a range of outcomes.

Results: From an initial pool of 126,689,864 person-months of observation, we generated final 64 matched cohorts of 208,536 Veterans infected between March 2020-April 2021 and 3,014,091 65 uninfected Veterans. Matched cohorts were well-balanced on all 38 covariates used in matching 66 after excluding patients for: no VA health care utilization; implausible age, weight, or height; 67 living outside of the 50 states or Washington, D.C.; prior SARS-CoV-2 diagnosis per Medicare 68 claims; or lack of a suitable match. Most Veterans in the matched cohort were male (88.3%), 69 70 non-Hispanic (87.1%), white (67.2%), and living in urban areas (71.5%), with a mean age of 60.6, BMI of 31.3, Gagne comorbidity score of 1.4 and a mean of 2.3 CDC high-risk conditions. 71 The most common diagnoses were hypertension (61.4%), diabetes (34.3%), major depression 72

73 (32.2%), coronary heart disease (28.5%), PTSD (25.5%), anxiety (22.5%), and chronic kidney

74 disease (22.5%).

- **Conclusions:** This successful creation of matched SARS-CoV-2 infected and uninfected patient
- cohorts from the largest integrated health system in the United States will support cohort studies
- of outcomes derived from EHRs and sample selection for qualitative interviews and patient
- surveys. These studies will increase our understanding of the long-term outcomes of Veterans
- 79 who were infected with SARS-CoV-2.
- 80 Key words: COVID-19, Veterans, matching, study design, retrospective, causal inference,
- 81 longitudinal

110 Background

111	The U.S. faces continued infections with Severe Acute Respiratory Syndrome
112	Coronavirus 2 (SARS-CoV-2) following earlier waves in 2020 and 2021. Numerous studies
113	have examined short-term symptoms, hospitalization, and death(1, 2) among patients infected
114	with SARS-CoV-2 both before and after vaccine availability. The coronavirus disease 2019
115	(COVID-19) pandemic caused unprecedented disruptions across a wide range of domains
116	relevant to health and health care including to health systems and care processes, informal family
117	support, long-term care, safety net programs, social organizations, and economic stability,
118	making it challenging to isolate the direct impact of infection with SARS-CoV-2 on individual
119	health. Thus, more work is needed to characterize the direct long-term health effects of SARS-
120	CoV-2 infection distinct from these systemic disruptions.
121	To research the long-term health consequences of COVID-19, the U.S. Department of
122	Veterans Affairs (VA) provided resources in May 2021 to create the COVID-19 Outcomes
123	Research Collaboratory (CORC). The main purposes of this program are investigating long-term
124	health outcomes associated with SARS-CoV-2 infection using national electronic health record
125	(EHR) data and survey research to assess factors not well captured by the EHR. The focus of
126	this paper is on the study design utilized to facilitate EHR research through cohort construction
127	of Veterans with SARS-CoV-2 infection and well-matched controls, with matching for a wide
128	range of covariates potentially associated with the exposure (SARS-CoV-2 infection) and
129	outcomes. The creation of these populations will enable study of outcomes associated with this
130	infection and potential mediating factors using observational research methods applied to both
131	retrospective EHR and prospective survey-based data.

To best identify potential causal associations, we selected the target trial emulation 132 approach to evaluate the causal effect of SARS-CoV-2 infection on long-term health-related 133 outcomes. This approach is intended to minimize sources of bias, including observed and 134 unobserved confounding and immortal time bias in estimating the effect of SARS-CoV-2 135 infection.(3, 4) To address unobserved confounding and selection bias, we matched Veterans 136 infected with SARS-CoV-2 to similar contemporaneous uninfected Veterans before comparing a 137 broad array of outcomes available in the VA's comprehensive longitudinal EHR. 138 Analyses based on the EHR will be supplemented with a prospective longitudinal survey 139 140 in which a subset of matched cohorts of infected and uninfected persons will be invited to participate. Longitudinal survey responses will provide more detailed information on patient-141 reported outcomes that will complement outcomes ascertained from the EHR. Selection and 142 matching of survey samples will be conducted in such a way to ensure covariate balance is 143 maintained in the survey subsample. In addition, source data from the EHR and survey will be 144 used to guide purposive sampling for a prospective qualitative study to understand the diversity 145 of experiences of Veterans infected with SARS-CoV-2. 146 Designing a matched cohort study to address a wide array of EHR-based outcomes and 147

embedded survey subsets requires a more inclusive consideration of confounding than when estimating the effect of SARS-CoV-2 infection on a single outcome. This protocol paper describes the design and methodological approach to identify a matched cohort of comparable patients infected and not infected with SARS-CoV-2. This matched cohort will be used in future research to analyze the effect of SARS-CoV-2 infection on clinical, functional, and economic outcomes among Veterans. This work could also inform and support efforts by other groups

interested in creating matched cohorts to address a wide range of unanswered questions related to
 SARS-CoV-2 infection.

156

157 Methods

158 Study Design and Data

We designed a retrospective cohort study of EHR-based outcomes with a non-equivalent comparator of uninfected Veterans. To facilitate measurement of patient-reported outcomes, this retrospective cohort is paired with an embedded smaller post-only survey-based prospective cohort study. In both components, comparator non-equivalence was reduced by generating matched cohorts.

As described previously,(5) we assembled a cohort of VA enrollees who tested positive 164 for SARS-CoV-2 RNA in a respiratory specimen within the VA system based on polymerase 165 chain reaction (PCR) tests as well as those with such tests performed outside the VA but 166 documented in VA records as identified by the VA National Surveillance Tool between March 167 1, 2020 and April 30, 2021. The earliest date of a documented positive test was taken as each 168 patient's date of infection. We included only those Veterans who had an assigned VA primary 169 care team (e.g., Patient Aligned Care Team) or at least one VA primary care clinic visit in the 170 two-year period prior to infection to minimize missingness in EHR-based covariates that are 171 generated from health system interaction. Cohorts were identified sequentially on a monthly 172 173 basis, with assignment to a particular month for cases based on the date of the positive test. VA-174 enrolled Veterans without a positive test prior to or during the month who met the same inclusion criteria were considered uninfected potential comparators for that month. The uninfected control 175 176 group members were eligible for repeated sampling and matching with replacement until they

had a positive test. To avoid misclassification of first infection date based on a positive test,
infected Veterans with COVID-19-related diagnostic codes (ICD-10: B97.29, U07.1, J12.82,
Z86.16) listed in fee-for-service Medicare claims 15 or more days before their VA test were
excluded. In addition, Veterans from the uninfected comparator group with any such diagnostic
codes were excluded from sampling for matching in the month the COVID-19-related code arose
and any months thereafter.

We developed 14 separate monthly patient cohorts—one for each month (March 2020-183 April 2021) — for the purpose of defining index dates and matching covariates. For example, the 184 185 March 2020 cohort included all VA enrollees with an initial positive test during March 2020 and all VA enrollees who were alive as of March 1, 2020 and had not been infected prior to April 1, 186 2020. SARS-CoV-2-infected patients were included as potential comparator patients in months 187 before infection. In a given month, uninfected Veterans could be matched to multiple infected 188 Veterans in that same month and uninfected Veterans could be included in multiple month-189 specific cohorts as long as they remained uninfected and continued to meet other eligibility 190 191 criteria. To minimize immortal time bias, the index date was defined as the date of the earliest positive test for SARS-CoV-2- infected Veterans and as the 1st day of the relevant month for 192 uninfected Veterans.(6) Each patient's index date served as the anchor for defining matching 193 covariates (with covariate construction starting 14 days prior to the positive test date for infected 194 patients), based on EHR data from the prior two years. 195

196

197 *Matching Specification*

Our goal was to conduct many-to-one matching that would maximize retention of
 infected patients for external validity and covariate balance for internal validity. A priori, we

defined a suitable matching strategy as one that would result in <5% attrition of the infected cohort and achieve covariate balance among the selected covariates for matching based on standardized differences <0.1.(7)

Coarsened exact matching (CEM) was initially attempted. Covariates used for matching were derived iteratively at a single point in time (summer 2021) with the understanding that the evidence base about causes and consequences of COVID-19 was (and is) evolving rapidly. In collaboration with clinician-investigators (see left column, Appendix 1), we identified a broad list of demographic, clinical, and health care utilization measures hypothesized to be either risk factors for pre-specified outcomes alone (e.g., survival, depression, total VA costs, disability, financial toxicity) or confounders associated with both infection and outcomes.(8)

To minimize sample loss when attempting to match on many covariates in CEM,(9) the 210 five physician principal investigators then worked together to prioritize covariates for the final 211 matching specification (see right column, Appendix 1). Modified coarsened exact matching was 212 then implemented using this prioritized set of covariates. However, a suitable exact match could 213 not be identified for 53.7% of infected Veterans, so we reverted to a form of combined exact and 214 calendar time-specific propensity score matching,(10) with cohorts identified by index month. 215 In a two-step process, infected patients were exact matched to uninfected controls based 216 on index month, sex, immunosuppressive medication use (binary), state of residence, and 217 COVID-19 vaccination status (effective in January-April 2021 cohorts only) because these 218 219 covariates were strong potential confounders. In the second step, a total of 38 binary, categorical, and continuous covariates were included in the propensity score model, including 220

immunosuppressive medication use (binary), nursing home residence any time, and diagnosed

222 CDC high-risk conditions:(11) coronary heart disease, cancer (excluding non-metastatic skin

cancers), chronic kidney disease, congestive heart failure, pulmonary-associated conditions
(including asthma, COPD, interstitial lung disease, and cystic fibrosis), dementia, diabetes,
hypertension, liver disease, sickle cell/thalassemia, solid organ or blood stem cell transplant,
stroke/cerebrovascular disorders, substance use disorder, anxiety disorder, bipolar disorder,
major depression, PTSD, and schizophrenia.

Other categorical variables in the propensity score model included sex, race, ethnicity, rurality of the Veteran's home ZIP code, state of residence, smoking status, and categorization of two comorbidity scores (CAN(12), Nosos(13)). Continuous covariates included age, body mass index (BMI), comorbidity score via Gagne index, distance from a Veteran's home to nearest VA hospital, count of CDC high-risk conditions, count of mental health conditions, and four VA utilization measures (inpatient admissions, primary care visits, specialty care visits, mental health visits in the prior 2 years).

A caliper of 0.2 times the pooled estimate of the standard deviation of the logit of the 235 propensity score was used to bound which uninfected patients could be matched to each infected 236 patient.(14) To provide the survey team a sufficiently deep pool of matched controls to account 237 for survey non-participation, the 25 matched uninfected patients closest in propensity score were 238 retained for each infected patient. Infected patients with fewer than 25 matched uninfected 239 patients had all their comparator patients selected as eligible matches. Matching was performed 240 by the PSMATCH procedure from SAS/STAT 15.1 in SAS® 9.4M6 via the VA Informatics and 241 Computing Infrastructure (VINCI) platform. 242

243

244

246 Outcomes Comparisons to be Conducted

The EHR-based clinical outcomes that we intend to compare between matched cohorts 247 are mortality, depression, suicide, onset of new clinical diagnoses, exacerbation of prevalent 248 conditions, development of COVID-19 sequelae, health care use, and costs. The survey-based 249 outcomes to be compared between matched cohorts include disability, financial toxicity, and 250 health-related quality of life. For all analyses, we take a "per-protocol" approach such that 251 uninfected patients who cross over to become infected will be censored at the time of infection. 252 The study team discussed inclusion of negative control outcomes, but an outcome expected to be 253 null between comparators could not be identified due to the ubiquitous effects of SARS-CoV-2 254 infection and the conditioning of negative control outcomes on health care utilization that might 255 be differential between comparators. 256

257

258 **Results**

From a sampling frame of 231,160 Veterans who had documentation of at least one 259 SARS-CoV-2 infection between March 2020 and April 2021, and 9,291,822 Veterans without 260 evidence of infection over the same time period, we excluded patients for missing comorbidity 261 (CAN) score, no primary care use 24 months prior to index, missing or implausible height, 262 weight, or age (Figure 1). We also excluded Veterans with missing ZIP codes or ZIP codes 263 outside of Washington, D.C. or the 50 states, patients who were uninfected on the 1st of each 264 month but became infected later in the same month (for the uninfected group), or had a prior 265 infection documented in Medicare. Lastly, we excluded 776 (0.4%) of 209,312 infected patients 266 who did not have a suitable match, which generated final matched cohorts of 208,536 infected 267

and 3,014,091 uninfected Veterans (comprising 5,173,400 total person-months of follow-up
because of matching with replacement).

270	The matched cohorts were well-balanced on all covariates, based on standardized mean
271	differences (SMD) <0.1 (Table 1). The cohorts included Veterans from all 50 states and
272	Washington, D.C. Most Veterans in the matched cohorts were male (88.3%), non-Hispanic
273	(87.1%), white (67.2%), and living in urban areas (71.5%), with a mean (standard deviation, SD)
274	age of 60.6 (16.4), BMI of 31.3 (6.6), and mean (SD) straight-line distance to the closest VA
275	medical center of 35.8 (35.2) miles. A minority were current smokers (12.6%), 39.3% had never
276	smoked and 42.5% were former smokers. Comorbidity was assessed several ways, including
277	Gagne score (mean=1.4, SD=2.2), count of CDC high-risk conditions (mean=2.3, SD=1.9) and
278	count of 5 mental health conditions prevalent in Veterans (mean=0.9, SD=1.0). The most
279	common diagnoses were hypertension (61.4%), diabetes (34.3%), major depression (32.2%),
280	coronary heart disease (28.5%), PTSD (25.5%), anxiety (22.5%), and chronic kidney disease
281	(22.5%). Approximately 10% of matched cohort members had been prescribed one or more
282	immunosuppressive medications within 24 months before the index date. Of the 34.0% of the
283	cohort with index dates between January-April 2021 when vaccinations became available,
284	70,985 Veterans (1.5% of the entire infected cohort) received at least one dose of a vaccine
285	before their first positive COVID-19 test result.
286	In the 24 months prior to the index date, cohort members had a mean (SD) of 8.3 (10.2)

primary care visits, 13.4 (14.9) specialty care visits, and 7.8 (21.9) mental health visits in VA.

Over one-half (53.3%) of infected patients were drawn from three of the 14 months in the

observation period (November 2020, December 2020, and January 2021).

291 Discussion

Despite the very large sample size available for this research with 231,160 infected and 292 just over 9 million uninfected Veterans, a strategy of bias reduction based on coarsened exact 293 matching on resulted in lack of an exact match for 53.7% of cases. The large sample loss reduced 294 statistical power and generalizability since the exposure-disease associations may have differed 295 296 between successfully matched and unmatched populations. The combined exact matching and propensity score approach, on the other hand, resulted in a much lower failure to match 297 frequency at only 0.4%, with a high rate of success as assessed by the SMDs < 0.1 for all 298 299 matching covariates. The work performed by the CORC to identify important covariates on which to and match cases and uninfected controls using propensity score methodology should 300 facilitate the performance of causal research on long COVID-19 etiology in this population. 301 Matched cohorts will be updated from May 2021 forward to be able to generate evidence on 302 Veteran experience after April 2021. 303

As the nation's largest national integrated publicly financed health system, the VA has the unique ability to track long-term outcomes among individuals infected with SARS-CoV-2 because it has a well-established comprehensive EHR that was developed around the mission of providing lifelong care for Veterans. In addition, Veterans are historically reliant on VA for care if they engage with the health system.

Our matching strategy defines the specific effect that will be estimated from our results. We considered historical controls of Veterans receiving care in the VA before the pandemic, but that would estimate the effect of individual SARS-CoV-2 infection combined with all the many other social and systematic disruptions that accompanied the pandemic. We also considered comparing Veterans hospitalized with SARS-CoV-2 infection to Veterans hospitalized with

other conditions (e.g., influenza), which would be analogous to a randomized clinical trial with an active comparator. Such a comparator group asks whether COVID-19 hospitalization is worse than other sorts of hospitalizations. We reasoned that, for most Veterans, had they not developed COVID-19, they may not have been hospitalized with another condition that same month (although we did not exclude those hospitalized, so they do occur at whatever their natural frequency is in the comparator group).

We also did not wish to restrict to only hospitalized COVID-19 patients, as we took as a 320 scientific question the relationship between initial severity of SARS-CoV-2 infection and 321 322 subsequent outcomes—rather than presuming it by conditioning on initial severity. We also considered Veterans infected with other non-SARS-CoV-2 viruses. However, we noted the 323 substantial body of evidence on sepsis and pneumonia-much of it viral in origin-that 324 suggested such patients also have adverse long-term outcomes caused by non-SARS-CoV-2 325 viruses, including influenza. As such, we reasoned such comparators might underestimate the 326 total individual effects survivors of COVID-19 would face and health systems would need to 327 support. Each of these comparators may be of great interest to other research groups; they were 328 not, however, our primary focus. Our goal was to generate matched cohorts to support cohort 329 studies of EHR-derived outcomes and sample selection for qualitative interviews and patient 330 surveys. 331

The retrospective cohort study described here is subject to several limitations. First, cohort matching results in sample loss that may reduce generalizability of results compared to weighting methods, although we were able to retain >99% of the infected patients in the sample after matching. Second, there is likely some contamination of the uninfected comparator group with Veterans with undiagnosed SARS-CoV-2 infection or who tested positive for SARS-CoV-2

337	with test results not available from private insurers, Medicare Advantage plans, Medicaid, or
338	other community sources. Third, covariate specification for matching is based on our
339	understanding of risk factors and confounders of SARS-CoV-2 infection as of spring 2022.
340	Fourth, results may not generalize to Veterans who became infected after April 2021 or to non-
341	Veterans. CORC will update matched cohorts from May 2021-March 2022, but that work is
342	ongoing.

343

344 Conclusions

Our understanding of the long-term outcomes of Veterans who were infected with SARS-345 CoV-2 will be gleaned from qualitative interviews, population-based surveys, and cohort studies 346 of outcomes derived from EHRs. This study will explore all these approaches, all framed in the 347 context of the matched cohorts generated from EHR data from the largest integrated health 348 system in the U.S. Due to Veterans' reliance on VA for care and eligibility for care once 349 enrolled, we will be able to evaluate clinical and economic outcomes following their acute 350 SARS-CoV-2 infection, as long-term outcomes two years after the onset of the pandemic are 351 now being realized. 352

353

354 **ABBREVIATIONS:**

355 CAN: Care Assessment Need; CDC: Centers for Disease Control and Prevention; COPD:

356 chronic obstructive pulmonary disease; CAD: coronary heart disease; HIV: human

immunodeficiency virus; CKD: chronic kidney disease; CHF: congestive heart failure; SUD:

substance use disorder; SMI: serious mental illness; PTSD: post-traumatic stress disorder; VA:

359 Veterans Health Administration; CBOC: VA community-based outpatient clinic.

360 **DECLARATIONS**

- 361 **Ethics approval and consent to participate:** Initial and continuing reviews approved by were
- reviewed and approved by the Durham Veterans Affairs Institutional Review Board and
- 363 Research and Development Committee. All methods were carried out in accordance with
- relevant guidelines and regulations. No informed consent was obtained because the project is
- 365 secondary analysis of data. The Durham VA Institutional Review Board granted waivers for
- informed consent, HIPAA information, and HIPAA research on decedents.
- 367 **Consent for publication:** Not applicable.
- 368 Availability of data and materials: The datasets generated and/or analyzed during the current
- 369 study are not publicly available due to Department of Veterans Affairs data restrictions
- prohibiting sharing. Contact the corresponding, Dr. Matthew Maciejewski, for data requests.
- 371 Matthew L. Maciejewski, Ph.D.
- 372 Department of Population Health Sciences
- 373Duke University Medical Center
- 374 Durham, NC 27705
- 375 Phone: (919) 286-0411 ext. 5198
- 376 e-mail: <u>mlm34@duke.edu</u>377
- 378 **Competing interests:** The authors declare that they have no competing interests.
- **Funding/Support:** The study was supported by the U.S. Department of Veterans Affairs
- HSR&D grant C19 21-278 and C19 21-279. MM was also supported by a senior Research
- 381 Career Scientist award from the Department of Veterans Affairs (RCS 10-391 to M.M. and RCS
- 382 21-136 to D.H.) and by the Durham VA Center of Innovation to Accelerate Discovery and
- 383 Practice Transformation (CIN 13-410).
- Authors' contributions: Conception: VAS, TSZB, PH, ESW, MN, JAP, KB, ASB, DH, EJB,
- 385 GNI, TJI, CBB, AMO, MLM.
- Design of the work: VAS, TSZB, PH, ESW, MN, JAP, ASB, DH, EJB, GNI, TJI, CBB, AMO,

- 387 MLM.
- 388 Data acquisition: TSZB, KB, PG, AK, AF, AB, AH, TAS, GNI.
- 389 Analysis: VAS, TSZB, KB, MLM
- Interpretation of data: VAS, TSZB, PH, MN, JAP, KB, ASB, DH, EJB, GNI, TJI, CBB, AMO,
- 391 MLM
- 392 Drafted work: VAS, TSZB, MLM
- 393 Substantive revision: VAS, TSZB, PH, ESW, MN, JAP, KB, PG, AK, AF, AB, AH, TAS, ASB,
- 394 DH, EJB, GNI, TJI, CBB, AMO, MLM
- **Role of the Sponsor:** The Health Services Research and Development Service, Department of
- 396 Veterans Affairs had no role in the design, conduct, collection, management, analysis, or
- interpretation of the data; or in the preparation, review, or approval of the manuscript. The
- opinions expressed are those of the authors and not necessarily those of the Department of
- Veterans Affairs, the United States Government, Duke University, the University of Washington,
- 400 the University of Michigan, Oregon Health & Science University (OHSU), Portland State
- 401 University, and Oregon State University.

402 **REFERENCES**

- 403 1. Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of
- 404 COVID-19. Nature. 2021;594(7862):259-64.
- 405 2. Groff D, Sun A, Ssentongo AE, Ba DM, Parsons N, Poudel GR, et al. Short-term and
- 406 Long-term Rates of Postacute Sequelae of SARS-CoV-2 Infection: A Systematic Review. JAMA
- 407 Netw Open. 2021;4(10):e2128568.
- 408 3. Hernan MA, Alonso A, Logan R, Grodstein F, Michels KB, Willett WC, et al.

409 Observational studies analyzed like randomized experiments: an application to postmenopausal

410 hormone therapy and coronary heart disease. Epidemiology. 2008;19(6):766-79.

411 4. Hernan MA, Robins JM. Using Big Data to Emulate a Target Trial When a Randomized

412 Trial Is Not Available. Am J Epidemiol. 2016;183(8):758-64.

413 5. Ioannou GN, Ferguson JM, O'Hare AM, Bohnert ASB, Backus LI, Boyko EJ, et al.

414 Changes in the associations of race and rurality with SARS-CoV-2 infection, mortality, and case

- fatality in the United States from February 2020 to March 2021: A population-based cohort
- 416 study. PLoS Med. 2021;18(10):e1003807.
- 417 6. Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol.

418 2008;167(4):492-9.

Austin PC. A Tutorial and Case Study in Propensity Score Analysis: An Application to
Estimating the Effect of In-Hospital Smoking Cessation Counseling on Mortality. Multivariate
Behav Res. 2011;46(1):119-51.

8. Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, Sturmer T. Variable
selection for propensity score models. Am J Epidemiol. 2006;163(12):1149-56.

- 424 9. Ripollone JE, Huybrechts KF, Rothman KJ, Ferguson RE, Franklin JM. Evaluating the
- 425 Utility of Coarsened Exact Matching for Pharmacoepidemiology Using Real and Simulated
- 426 Claims Data. Am J Epidemiol. 2020;189(6):613-22.
- 427 10. Mack CD, Glynn RJ, Brookhart MA, Carpenter WR, Meyer AM, Sandler RS, et al.
- 428 Calendar time-specific propensity scores and comparative effectiveness research for stage III
- 429 colon cancer chemotherapy. Pharmacoepidemiol Drug Saf. 2013;22(8):810-8.
- 430 11. Prevention CfDCa. Underlying Medical Conditions Associated with Higher Risk for
- 431 Severe COVID-19: Information for Healthcare Professionals Atlanta, GA: Centers for Disease
- 432 Control and Prevention; 2022 [Available from: https://www.cdc.gov/coronavirus/2019-
- 433 <u>ncov/hcp/clinical-care/underlyingconditions.html</u>.
- 434 12. Wang L, Porter B, Maynard C, Evans G, Bryson C, Sun H, et al. Predicting risk of
- hospitalization or death among patients receiving primary care in the Veterans Health
- 436 Administration. Med Care. 2013;51(4):368-73.
- 437 13. Wagner TH, Upadhyay A, Cowgill E, Stefos T, Moran E, Asch SM, et al. Risk
- Adjustment Tools for Learning Health Systems: A Comparison of DxCG and CMS-HCC V21.
- 439 Health Serv Res. 2016;51(5):2002-19.
- 440 14. Austin PC. Optimal caliper widths for propensity-score matching when estimating
- differences in means and differences in proportions in observational studies. Pharm Stat.
- 442 2011;10(2):150-61.

Table 1. Descriptive Statistics of Matched Cohorts


Variable Name	COVID-19	Uninfected	SMD
	(n=208,536)	(n=5,173,400)	
Age, mean (SD)	60.6 (16.2)	60.6 (16.4)	0.00106
BMI, mean (SD)	31.3 (6.4)	31.3 (6.6)	0.01178
Sex, N (%)			
Female	21,949 (10.5)	540,127 (10.4)	
Male	183,676 (88.1)	4,566,632 (88.3)	0.00988
Unknown	2,911 (1.4)	66,641 (1.3)	
Race, N (%)			
American Indian/Alaska Native	1,965 (0.9)	47,784 (0.9)	
Asian	2,081 (1.0)	51,718 (1.0)	
Black or African American	47,726 (22.9)	1,189,212 (23.0)	
Native Hawaiian or Other Pacific Islander	1,946 (0.9)	48,095 (0.9)	0.00610
White	139,952 (67.1)	3,474,658 (67.2)	0.00010
Multiple Races	1,978 (0.9)	49,028 (0.9)	
Missing	12,888 (6.2)	312,905 (6.0)	-
Hispanic Ethnicity, N (%)			
Yes	20,309 (9.7)	492,607 (9.5)	
No	181,097 (86.8)	4,506,252 (87.1)	0.00792
Missing	7,130 (3.4)	174,541 (3.4)	
Rurality, N (%)			
Urban	149,310 (71.6)	3,700,754 (71.5)	0.00144
Not Urban (incl. missing)	59,226 (28.4)	1,472,646 (28.5)	-
Smoking Status, N (%)			
Current	26,188 (12.6)	654,415 (12.6)	
Former	88,275 (42.3)	2,201,135 (42.5)	0.01379
Never	81,916 (39.3)	2,032,442 (39.3)	
Missing	12,157 (5.8)	285,408 (5.5)	
CDC High Risk Conditions, N (%)			
Coronary Heart Disease	59,972 (28.8)	1,472,173 (28.5)	0.00668
Cancer	38,136 (18.3)	942,791 (18.2)	0.00165
Chronic Kidney Disease	47,610 (22.8)	1,161,200 (22.4)	0.00920
Congestive Heart Failure	22,124 (10.6)	532,106 (10.3)	0.01059
Pulmonary	46,178 (22.1)	1,131,201 (21.9)	0.00671
Dementia	10,837 (5.2)	254,136 (4.9)	0.01298
Diabetes	72,020 (34.5)	1,773,699 (34.3)	0.00528
Hypertension	127,761 (61.3)	3,174,235 (61.4)	0.00187

Liver Disease	15,324 (7.3)	370,974 (7.2)	0.00684
Sickle Cell	383 (0.2)	9,131 (0.2)	0.00169
Transplant	687 (0.3)	16,864 (0.3)	0.00061
Stroke/Cerebrovascular disease	13,012 (6.2)	314,234 (6.1)	0.00689
Substance Use Disorder	25,915 (12.4)	645,302 (12.5)	0.00140
Anxiety	47,186 (22.6)	1,165,628 (22.5)	0.00230
Bipolar disorder	8,039 (3.9)	199,388 (3.9)	0.00005
Major Depression	67,383 (32.3)	1,664,825 (32.2)	0.00282
PTSD	52,964 (25.4)	1,317,278 (25.5)	0.00148
Schizophrenia	4,737 (2.3)	115,145 (2.2)	0.00309
# CDC High Risk Conditions, mean (SD)	2.3 (1.9)	2.3 (1.9)	0.01088
# Mental Health Conditions (Anxiety,	0.9 (1.1)	0.9 (1.0)	0.00200
Bipolar disorder, major depression, PTSD, schizophrenia), mean (SD)			
Gagne score, mean (SD)	1.4 (2.3)	1.4 (2.2)	0.01559
# VA Inpatient Admissions, mean (SD)	0.4 (1.2)	0.4 (1.3)	0.00079
# VA Primary Care Visits, mean (SD)	8.6 (9.7)	8.3 (10.2)	0.02916
# VA Specialty Care Visits, mean (SD)	13.9 (14.1)	13.4 (14.9)	0.03288
Mental Health Care Utilization, mean (SD)	7.9 (22.6)	7.8 (21.9)	0.00457
Immunosuppressed in prior 24 months, N (%)	20,366 (9.8)	502,358 (9.7)	0.00188
CLC At Index Date, N (%)	2,176 (1.0)	46,586 (0.9)	0.01457
NOSOS score, N (%)			
NOSOS, missing	4,801 (2.3)	110,729 (2.1)	
NOSOS Category 1 [0, 0.417)	5,708 (2.7)	129,206 (2.5)	
NOSOS Category 2 [0.417, 0.471)	9,599 (4.6)	227,788 (4.4)	
NOSOS Category 3 [0.471, 0.534)	12,449 (6.0)	305,685 (5.9)	
NOSOS Category 4 [0.534, 0.611)	15,187 (7.3)	378,825 (7.3)	
NOSOS Category 5 [0.611, 0.707)	17,737 (8.5)	450,045 (8.7)	0.03224
NOSOS Category 6 [0.707, 0.829)	20,556 (9.9)	525,057 (10.1)	
NOSOS Category 7 [0.829, 0.998)	23,462 (11.3)	599,981 (11.6)	
NOSOS Category 8 [0.998, 1.259)	26,956 (12.9)	686,219 (13.3)	
NOSOS Category 9 [1.259, 1.805)	31,372 (15.0)	786,826 (15.2)	
NOSOS Category 10 [1.805, Inf)	40,709 (19.5)	973,039 (18.8)	
CAN Score, N (%)			
CAN, missing	4,066 (1.9)	86,041 (1.7)	
CAN Category 1, 0 – 20	34,427 (16.5)	851,737 (16.5)	0.000=0
CAN Category 2, 25 – 40	31,926 (15.3)	801,677 (15.5)	0.03258
CAN Category 3, 45 – 60	38,266 (18.3)	970,378 (18.8)	
CAN Category 4, 65 – 80	46,894 (22.5)	1,184,134 (22.9)	

CAN Category 5, 85 – 90	30,745 (14.7)	762,537 (14.7)	
CAN Category 6, 95 – 99	22,212 (10.7)	516,896 (10.0)	
Vaccinated in January-April 2021, N (%)	3,153 (1.5)	75,353 (1.5)	0.00470
Index Month, N (%)			
March 2020	2,340 (1.1)	58,278 (1.1)	
April 2020	6,786 (3.3)	168,727 (3.3)	-
May 2020	4,402 (2.1)	109,604 (2.1)	-
June 2020	6,967 (3.3)	173,776 (3.4)	-
July 2020	14,945 (7.2)	373,025 (7.2)	-
August 2020	8,376 (4.0)	208,750 (4.0)	-
September 2020	6,787 (3.3)	169,048 (3.3)	0.00363
October 2020	12,212 (5.9)	302,119 (5.8)	-
November 2020	31,004 (14.9)	767,646 (14.8)	-
December 2020	43,732 (21.0)	1,085,816 (21.0)	-
January 2021	36,282 (17.4)	900,381 (17.4)	-
February 2021	15,699 (7.5)	388,553 (7.5)	-
March 2021	9,942 (4.8)	244,839 (4.7)	-
April 2021	9,062 (4.3)	222,838 (4.3)	-
U.S. State of Residence, N (%)			-
Alaska	694 (0.3)	16,880 (0.3)	
Alabama	4,089 (2.0)	101,648 (2.0)	-
Arkansas	3,075 (1.5)	76,426 (1.5)	-
Arizona	6,310 (3.0)	157,105 (3.0)	-
California	16,253 (7.8)	405,136 (7.8)	
Colorado	3,278 (1.6)	80,733 (1.6)	
Connecticut	1,895 (0.9)	46,782 (0.9)	
Washington, D.C.	414 (0.2)	10,111 (0.2)	
Delaware	552 (0.3)	13,199 (0.3)	
Florida	16,003 (7.7)	399,175 (7.7)	-
Georgia	7,893 (3.8)	196,375 (3.8)	-
Hawaii	263 (0.1)	6,295 (0.1)	0.01515
Iowa	2,473 (1.2)	59,479 (1.1)	-
Idaho	1,582 (0.8)	39,124 (0.8)	-
Illinois	6,462 (3.1)	159,840 (3.1)	
Indiana	4,533 (2.2)	112,806 (2.2)	
Kansas	2,471 (1.2)	61,282 (1.2)	
Kentucky	3,352 (1.6)	82,956 (1.6)	
Louisiana	3,754 (1.8)	93,423 (1.8)]
Massachusetts	2,990 (1.4)	73,840 (1.4)	1

Maryland	2,640 (1.3)	65,047 (1.3)	
Maine	631 (0.3)	15,442 (0.3)	
Michigan	4,383 (2.1)	108,714 (2.1)	
Minnesota	4,251 (2.0)	105,503 (2.0)	
Missouri	6,609 (3.2)	164,281 (3.2)	
Mississippi	1,804 (0.9)	44,823 (0.9)	
Montana	1,122 (0.5)	27,824 (0.5)	_
North Carolina	8,521 (4.1)	212,232 (4.1)	_
North Dakota	865 (0.4)	21,154 (0.4)	
Nebraska	1,872 (0.9)	46,270 (0.9)	
New Hampshire	743 (0.4)	18,024 (0.3)	
New Jersey	2,623 (1.3)	64,850 (1.3)	
New Mexico	1,373 (0.7)	34,024 (0.7)	
Nevada	3,049 (1.5)	75,467 (1.5)	
New York	7,739 (3.7)	192,659 (3.7)	
Ohio	9,173 (4.4)	228,564 (4.4)	_
Oklahoma	4,030 (1.9)	100,147 (1.9)	
Oregon	1,386 (0.7)	34,259 (0.7)	_
Pennsylvania	7,880 (3.8)	196,104 (3.8)	_
Rhode Island	762 (0.4)	18,729 (0.4)	_
South Carolina	6,352 (3.0)	157,970 (3.1)	_
South Dakota	1,408 (0.7)	29,278 (0.6)	_
Tennessee	5,848 (2.8)	145,295 (2.8)	_
Texas	19,436 (9.3)	485,224 (9.4)	-
Utah	1,243 (0.6)	30,706 (0.6)	
Virginia	5,070 (2.4)	125,759 (2.4)	
Vermont	149 (0.1)	3,594 (0.1)	
Washington	1,976 (0.9)	48,855 (0.9)	
Wisconsin	5,087 (2.4)	126,171 (2.4)	
West Virginia	1,621 (0.8)	40,213 (0.8)	
Wyoming	554 (0.3)	13,603 (0.3)	
stance to Nearest VAMC (miles), mean	35.6 (36.5)	35.8 (35.1)	0.0045

Note: The uninfected cohort represents 3,014,091 unique Veterans with a total of 5,173,400 person-months since they were matched with replacement.





Appendix 1. Original and Final List of Covariates for Matching			
Original Covariate List	Final Matching Specification Used		
Sex	Sex		
Use of immunosuppressive medication	Use of immunosuppressive medication		
Age	Age		
Race	Race		
Ethnicity	Ethnicity		
CAN comorbidity score	CAN comorbidity score (7 categories)		
Nosos comorbidity score	Nosos comorbidity score (11 categories)		
Gagne comorbidity score indicators	Gagne comorbidity score		
Indicator of CDC high-risk conditions (Cancer other	Indicator of CDC high-risk conditions (Cancer other		
than non-metastatic skin cancer)	than non-metastatic skin cancer)		
Indicator of CDC high-risk conditions	Indicator of CDC high-risk conditions		
(COPD/asthma/interstitial lung disease/cystic	(COPD/asthma/interstitial lung disease/cystic		
fibrosis/pulmonary)	fibrosis/pulmonary)		
Indicator of CDC high-risk conditions (hypertension)	Indicator of CDC high-risk conditions (hypertension)		
Indicator of CDC high-risk conditions (diabetes)	Indicator of CDC high-risk conditions (diabetes)		
Indicator of CDC high-risk conditions (Dementia)	Indicator of CDC high-risk conditions (Dementia)		
Indicator of CDC high-risk conditions (CAD)	Indicator of CDC high-risk conditions (CAD)		
Indicator of CDC high-risk conditions (HIV)			
Indicator of CDC high-risk conditions (Liver disease)	Indicator of CDC high-risk conditions (Liver disease)		
Indicator of CDC high-risk conditions (Pregnancy)	Indicator of CDC high-risk conditions (Pregnancy) ¹		
Indicator of CDC high-risk conditions (Sickle cell/	Indicator of CDC high-risk conditions (Sickle cell/		
thalassemia)	thalassemia)		
Indicator of CDC high-risk conditions (Smoking)	Smoking status (4 categories)		
Indicator of CDC high-risk conditions (Solid organ or	Indicator of CDC high-risk conditions (Solid organ or		
blood stem cell transplant)	blood stem cell transplant)		
Indicator of CDC high-risk conditions (Stroke or	Indicator of CDC high-risk conditions (Stroke or		
cerebrovascular disease)	cerebrovascular disease)		
Indicator of CDC high-risk conditions (CKD)	Indicator of CDC high-risk conditions (CKD)		
Indicator of CDC high-risk conditions (CHF)	Indicator of CDC high-risk conditions (CHF)		
Indicator of CDC high-risk conditions (SUD)	Indicator of CDC high-risk conditions (SUD)		
	Count of CDC high-risk conditions		
SMI Diagnosis			
Anxiety Diagnosis	Anxiety Diagnosis		
PTSD Diagnosis	PTSD Diagnosis		
Bipolar Diagnosis	Bipolar Diagnosis		
Schizophrenia Diagnosis	Schizophrenia Diagnosis		
	Major depression Diagnosis		
	Count of mental health conditions		
Body Mass Index (BMI)	Body Mass Index (BMI)		
Community Living Center resident	Community Living Center resident		
# VA telehealth visits			
# VA in-person outpatient visits			
# VA community care outpatient visits			
# VA admissions	# admissions (VA + non-VA)		
	# VA primary care visits		
	# VA specialty care visits		
	# VA mental health care visits		

Appendix 1. Original and Final List of Covariates for Matching

State of residence	State of residence	
Distance to nearest level 1a complexity VA facility		
Distance to nearest level 1b complexity VA facility		
Distance to nearest level 1c complexity VA facility	Distance to nearest VA medical center	
Distance to nearest level 2 complexity VA facility		
Distance to nearest level 3 complexity VA facility		
Distance to nearest level CBOC		
Rurality of residence	Rurality of residence (urban, rural)	
Vaccinated for SARS-CoV-2 (January-April 2021)	Vaccinated for SARS-CoV-2 (January-April 2021)	
Medicare enrolled (none, A only, A+B, A+B+D, MA)		

¹Pregnancy indicator variable was constructed from ICD-10 diagnosis codes but was 0 for all patients in both arms of the study cohort.

Abbreviations: CAN: Care Assessment Need; CDC: Centers for Disease Control and Prevention; COPD: chronic obstructive pulmonary disease; CAD: coronary heart disease; HIV: human immunodeficiency virus; CKD: chronic kidney disease; CHF: congestive heart failure; SUD: substance use disorder; SMI: serious mental illness; PTSD: post-traumatic stress disorder; VA: Veterans Health Administration; CBOC: VA community-based outpatient clinic